We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Vanda Pharmaceuticals, known for its aggressive awareness push on non-24 disorder, has mounted a new campaign focusing on a schizophrenia medication side effect that's less prevalent in patients taking its own drug Fanapt.